Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasIVe fungal disease in recipients of allogeneic stem-cell transplantation: A prospectIVe multicenter randomized phase IV trial

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 3999-4006

  Wan, Liping ^a   Zhang, Yicheng ^b   Lai, Yongrong ^c   Jiang, Ming ^d   Song, Yongping ^e   Zhou, Jianfeng ^b   Zhang, Zhongming ^c   Duan, Xianlin ^d   Fu, Yuewen ^e   Liao, Lianming ^f   Wang, Chun ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e Henan Cancer Hospital   (China)

^f FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; LEVOFLOXACIN; MICAFUNGIN; MOLGRAMOSTIM; VORICONAZOLE; ANTIFUNGAL AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; BLEEDING; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PHASE 4 CLINICAL TRIAL; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES CEREVISIAE; SYSTEMIC MYCOSIS; TREATMENT RESPONSE; ADOLESCENT; ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MYCOSES; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84951804323     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.5121     Document Type: Conference Paper

References (38)

1. Kurosawa M, Yonezumi M, Hashino S, et al: Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 96:748-757, 2012
2. Pagano L, Caira M, Nosari A, et al: Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study- Sorveglianza Epidemiological Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45:1161-1170, 2007
3. Mikulska M, Raiola AM, Bruno B, et al: Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: An analysis of 306 patients. Bone Marrow Transplant 44:361-370, 2009
4. Neofytos D, Horn D, Anaissie E, et al: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48:265-273, 2009
5. Pagano L, Caira M, Candoni A, et al: The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 91:1068-1075, 2006
6. Malagola M, Peli A, Damiani D, et al: Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: Retrospective analysis of 224 cases. Eur J Haematol 81:354-363, 2008
7. Pursell K, Verral S, Daraiesh F, et al: Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: In vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis 5:29-37, 2003
8. Ruef C, Coleman DL: Granulocytemacrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 12:41-62, 1990
9. Walsh TJ, Anaissie EJ, Denning DW, et al: Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360, 2008
10. Elhelu MA: The role of macrophages in immunology. J Natl Med Assoc 75:314-317, 1983
11. Quezada G, Koshkina NV, Zweidler-McKay P, et al: Intranasal granulocyte-macrophage colonystimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother 52:716-718, 2008
12. Sionov E, Mendlovic S, Segal E: Experimental systemic murine aspergillosis: Treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 56:594-597, 2005
13. Safdar A: Difficulties with fungal infections in acute myelogenous leukemia patients: Immune enhancement strategies. Oncologist 12:2-6, 2007 (suppl 2)
14. Baltch AL, Bopp LH, Smith RP, et al: Effects of voriconazole, granulocyte-macrophage colonystimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diagn Microbiol Infect Dis 52:299-304, 2005
15. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al: Interferon-gamma and granulocytemacrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 191: 1180-1187, 2005
16. Chen GH, Olszewski MA, McDonald RA, et al: Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am J Pathol 170:1028-1040, 2007
17. De Pauw B, Walsh TJ, Donnelly JP, et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group: European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821, 2008
18. Ji Y, Liu D, Xu L, et al: The value of serum galactomannan detection for diagnosis of invasive aspergillosis in hematopoietic stem cell transplant recipients. Zhonghua Xue Ye Za Zhi 28:83-86, 2007
19. Segal BH, Herbrecht R, Stevens DA, et al: Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47:674-683, 2008
20. Wingard JR, Ribaud P, Schlamm HT, et al: Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112:2309-2312, 2008
21. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295-304, 1974
22. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
23. Anderson JR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 38:407-416, 1982
24. Peters BG, Adkins DR, Harrison BR, et al: Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis. Bone Marrow Transplant 18:93-102, 1996
25. Clark OA, Lyman GH, Castro AA, et al: Colonystimulating factors for chemotherapy-induced febrile neutropenia: A meta-Analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005
26. Dekker A, Bulley S, Beyene J, et al: Metaanalysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 24:5207-5215, 2006
27. Lionakis MS, Swamydas M, Fischer BG, et al: CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest 123:5035-5051, 2013
28. de Repentigny L, Petitbois S, Boushira M, et al: Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun 61:3791-3802, 1993
29. Grimm MJ, Vethanayagam RR, Almyroudis NG, et al: Monocyte-And macrophage-targeted NADPH oxidase mediates antifungal host defense and regulation of acute inflammation in mice. J Immunol 190:4175-4184, 2013
30. Chai LY, Naesens R, Khoo AL, et al: Invasive fungal infection in an elderly patient with defective inflammatory macrophage function. Clin Microbiol Infect 17:1546-1549, 2011
31. Romani L: Immunity to fungal infections. Nat Rev Immunol 11:275-288, 2011
32. Gil-Lamaignere C, Winn RM, Simitsopoulou M, et al: Interferon gamma and granulocytemacrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: Comparison with Aspergillus spp. Med Mycol 43:253-260, 2005
33. Roilides E, Holmes A, Blake C, et al: Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 170:894-899, 1994
34. Gaviria JM, van Burik JA, Dale DC, et al: Comparison of interferon, granulocyte colonystimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocytemediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 179:1038-1041, 1999
35. Sullivan GW, Carper HT, Mandell GL: The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colonystimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 81:1863-1870, 1993
36. Meyer CN, Nielsen H: Priming of neutrophil and monocyte activation in human immunodeficiency virus infection: Comparison of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and interferon-gamma. APMIS 104:640-646, 1996
37. Ball LM, Egeler RM, European Blood and Marrow Transplantation Paediatric Working Party: Acute GvHD: Pathogenesis and classification. Bone Marrow Transplant 41:S58-S64, 2008 (suppl 2)
38. Ringden O, Hassan Z, Karlsson H, et al: Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 90:1022-1029, 2010